Role of the VEGF 936 gene polymorphism and VEGF-A levels in the late-term arteriovenous fistula thrombosis in patients undergoing hemodialysis

Vascular access is vital for hemodialysis patients. A major factor that facilitates arteriovenous (AV) fistula failure is stenosis and thrombosis due to intimal hyperplasia developing in the venous segment of AV fistula. It has been reported that VEGF accelerated re-endothelialization, reduction in intimal thickening, and/or mural thrombus formed in the injured vascular structures. In this study, we aimed to identify the effect of the VEGF 936 gene polymorphism and vascular endothelial growth factor-A (VEGF-A) levels in the late period of AV fistula loss in hemodialysis patients. The study was carried out with a patient group of 42 individuals who experienced two or more fistula thrombosis in the late period after the AV fistula operation and also a control group of 38 patients who have not had any AV fistula thrombosis history for 3 years or more. All participants were assessed for VEGF-936C/T gene polymorphism and VEGF-A levels. VEGF-936C/T genotypes were determined in the large proportion in the control group (31.6 %), while VEGF-936C/C genotypes were determined in a large proportion in the patient group (90.5 %). Individuals carrying the VEGF-936C/C genotype had an increased risk of 5.54 for getting AV fistula thrombosis. The VEGF-A levels of patient group (27.3 +/- A 43.5 pg/ml) were significantly lower than those of the control group (70.7 +/- A 53.1 pg/ml). There is an increased risk of AV fistula thrombosis in individuals carrying the VEGF-936C/C genotype. The other renal replacement modalities should be considered in patients with this genotype. As a result, it will be possible to prevent the morbidity and mortality due to fistula failure.

Yazar Candan, Ferhan
Yildiz, Gursel
Kayatas, Mansur
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/3287
Tek Biçim Adres 10.1007/s11255-014-0711-4
Konu Başlıkları AV fistula stenosis
Hemodialysis
VEGF gene polymorphism
VEGF-A
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı INTERNATIONAL UROLOGY AND NEPHROLOGY
Dergi Cilt Bilgisi 46
Dergi Sayısı 9
Sayfalar 1815 - 1823
Yayın Yılı 2014
Eser Adı
[dc.title]
Role of the VEGF 936 gene polymorphism and VEGF-A levels in the late-term arteriovenous fistula thrombosis in patients undergoing hemodialysis
Yazar
[dc.contributor.author]
Candan, Ferhan
Yazar
[dc.contributor.author]
Yildiz, Gursel
Yazar
[dc.contributor.author]
Kayatas, Mansur
Yayın Yılı
[dc.date.issued]
2014
Yayıncı
[dc.publisher]
SPRINGER
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Vascular access is vital for hemodialysis patients. A major factor that facilitates arteriovenous (AV) fistula failure is stenosis and thrombosis due to intimal hyperplasia developing in the venous segment of AV fistula. It has been reported that VEGF accelerated re-endothelialization, reduction in intimal thickening, and/or mural thrombus formed in the injured vascular structures. In this study, we aimed to identify the effect of the VEGF 936 gene polymorphism and vascular endothelial growth factor-A (VEGF-A) levels in the late period of AV fistula loss in hemodialysis patients. The study was carried out with a patient group of 42 individuals who experienced two or more fistula thrombosis in the late period after the AV fistula operation and also a control group of 38 patients who have not had any AV fistula thrombosis history for 3 years or more. All participants were assessed for VEGF-936C/T gene polymorphism and VEGF-A levels. VEGF-936C/T genotypes were determined in the large proportion in the control group (31.6 %), while VEGF-936C/C genotypes were determined in a large proportion in the patient group (90.5 %). Individuals carrying the VEGF-936C/C genotype had an increased risk of 5.54 for getting AV fistula thrombosis. The VEGF-A levels of patient group (27.3 +/- A 43.5 pg/ml) were significantly lower than those of the control group (70.7 +/- A 53.1 pg/ml). There is an increased risk of AV fistula thrombosis in individuals carrying the VEGF-936C/C genotype. The other renal replacement modalities should be considered in patients with this genotype. As a result, it will be possible to prevent the morbidity and mortality due to fistula failure.
Açıklama
[dc.description]
WOS: 000341430800022
Açıklama
[dc.description]
PubMed: 24748065
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
AV fistula stenosis
Konu Başlıkları
[dc.subject]
Hemodialysis
Konu Başlıkları
[dc.subject]
VEGF gene polymorphism
Konu Başlıkları
[dc.subject]
VEGF-A
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0301-1623
ISSN
[dc.identifier.issn]
1573-2584
İlk Sayfa Sayısı
[dc.identifier.startpage]
1815
Son Sayfa Sayısı
[dc.identifier.endpage]
1823
Dergi Adı
[dc.relation.journal]
INTERNATIONAL UROLOGY AND NEPHROLOGY
Dergi Sayısı
[dc.identifier.issue]
9
Dergi Cilt Bilgisi
[dc.identifier.volume]
46
Tek Biçim Adres
[dc.identifier.uri]
https://dx.doi.org/10.1007/s11255-014-0711-4
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/3287
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
34
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
18 Mayıs 2024 09:19
Google Kontrol
Tıklayınız
fistula thrombosis patients patient VEGF-936C/C control levels genotype period increased carrying polymorphism individuals proportion determined genotypes VEGF-A VEGF-936C/T pg/ml) hemodialysis intimal vascular failure result considered possible prevent morbidity assessed mortality modalities should participants getting significantly
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms